High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies
Jonathan Tschopp, A. Brunel, Olivier Spertini, Anthony Croxatto, Frédéric Lamoth, Pierre–Yves Bochud
Abstract
Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.
Topics & Concepts
MedicineAntibodyPopulationImmunologyInternal medicineEnvironmental healthAntifungal resistance and susceptibilityFungal Infections and StudiesCystic Fibrosis Research Advances